Oral liposomal delivery of an activatable budesonide prodrug reduces colitis in experimental mice

References

• Al-Jamal WT, Kostarelos K. (2011). Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc Chem Res 44:1–14.
   PubMed Web of Science ®Google Scholar
• Barenholz YC. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. J Controlled Release 160:117–34.
   PubMed Web of Science ®Google Scholar
• Bhattacharjee S. (2016). DLS and zeta potential—what they are and what they are not? J Control Release 235:337–51.
   PubMed Web of Science ®Google Scholar
• Caster JM, Patel AN, Zhang T, Wang A. (2017). Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials. Wiley Interdiscip Rev Nanomed Nanobiotechnol 9:e1416.
   Web of Science ®Google Scholar
• Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. (2014). Dextran sulfate sodium (DSS)-induced colitis in mice. Curr Protoc Immunol 104:15.25.
   Google Scholar
• Chelakkot C, Ghim J, Ryu SH. (2018). Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med 50:1–9.
   PubMed Web of Science ®Google Scholar
• Chen X, Cui L, Xu J, et al. (2022). De novo engineering of both an omega-3 fatty acid-derived nanocarrier host and a prodrug guest to potentiate drug efficacy against colorectal malignancies. Biomaterials 290:121814.
   PubMed Web of Science ®Google Scholar
• Chung CH, Jung W, Keum H, et al. (2020). Nanoparticles derived from the natural antioxidant rosmarinic acid ameliorate acute inflammatory bowel disease. ACS Nano 14:6887–96.
   PubMed Web of Science ®Google Scholar
• Das SK, Roy S, Kalimuthu Y, et al. (2012). Solid dispersions: an approach to enhance the bioavailability of poorly water-soluble drugs. Int J Pharmacol Pharm Technol 1:37–46.
   Google Scholar
• De Vos M, Mielants H, Cuvelier C, et al. (1996). Long-term evolution of gut inflammation in patients with spondyloarthropathy. Gastroenterology 110:1696–703.
   PubMed Web of Science ®Google Scholar
• Derendorf H, Meltzer EO. (2008). Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. Allergy 63:1292–300.
   PubMed Web of Science ®Google Scholar
• Djuricic I, Calder PC. (2021). Beneficial outcomes of omega-6 and omega-3 polyunsaturated fatty acids on human health: an update for 2021. Nutrients 13:2421.
   PubMed Web of Science ®Google Scholar
• Fang T, Ye Z, Wu J, Wang H. (2018). Reprogramming axial ligands facilitates the self-assembly of a platinum(iv) prodrug: overcoming drug resistance and safer in vivo delivery of cisplatin. Chem Commun (Camb) 54:9167–70.
   PubMed Web of Science ®Google Scholar
• Fedorak RN, Bistritz L. (2005). Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev 57:303–16.
   PubMed Web of Science ®Google Scholar
• Ferri D, Costero AM, Gavina P, et al. (2019). Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis. Int J Pharm 561:93–101.
   PubMedGoogle Scholar
• Grassucci RA, Taylor DJ, Frank J. (2007). Preparation of macromolecular complexes for cryo-electron microscopy. Nat Protoc 2:3239–46.
   PubMed Web of Science ®Google Scholar
• Haep L, Britzen-Laurent N, Weber TG, et al. (2015). Interferon gamma counteracts the angiogenic switch and induces vascular permeability in dextran sulfate sodium colitis in mice. Inflamm Bowel Dis 21:2360–71.
   PubMed Web of Science ®Google Scholar
• Han W, Xie B, Li Y, et al. (2019). Orally deliverable nanotherapeutics for the synergistic treatment of colitis-associated colorectal cancer. Theranostics 9:7458–73.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. (2002). New steroids for IBD: progress report. Gut 51:182–3.
   PubMed Web of Science ®Google Scholar
• He H, Yuan D, Wu Y, Cao Y. (2019). Pharmacokinetics and pharmacodynamics modeling and simulation systems to support the development and regulation of liposomal drugs. Pharmaceutics 11:110.
   PubMed Web of Science ®Google Scholar
• Herbada RS, Torres-Suárez AI, Otero-Espinar FJ, et al. (2021). Matrix tablets based on a novel poly (magnesium acrylate) hydrogel for the treatment of inflammatory bowel diseases. Int J Pharm 608:121121.
   PubMedGoogle Scholar
• Huang L, Wan J, Wu H, et al. (2021). Quantitative self-assembly of photoactivatable small molecular prodrug cocktails for safe and potent cancer chemo-photodynamic therapy. Nano Today 36:101030.
   Web of Science ®Google Scholar
• Ito R, Kita M, Shin-Ya M, et al. (2008). Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem Biophys Res Commun 377:12–6.
   PubMed Web of Science ®Google Scholar
• Jacobson JL, Jacobson SW, Muckle G, et al. (2008). Beneficial effects of a polyunsaturated fatty acid on infant development: evidence from the Inuit of Arctic Quebec. J Pediatr 152:356–64.
   PubMed Web of Science ®Google Scholar
• Jubeh TT, Nadler-Milbauer M, Barenholz Y, Rubinstein A. (2006). Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. J Drug Target 14:155–63.
   PubMed Web of Science ®Google Scholar
• Kaplan GG, Ng SC. (2017). Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 152:313–21.e2.
   PubMed Web of Science ®Google Scholar
• Kaur G, Arora M, Kumar MR. (2019). Oral drug delivery technologies—a decade of developments. J Pharmacol Exp Ther 370:529–43.
   PubMed Web of Science ®Google Scholar
• Kim JH, Hong SS, Lee M, et al. (2019). Krill oil-incorporated liposomes as an effective nanovehicle to ameliorate the inflammatory responses of DSS-induced colitis. Int J Nanomedicine 14:8305–20.
   PubMed Web of Science ®Google Scholar
• Kim JM, Kim DH, Park HJ, et al. (2020). Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model. J Nanobiotechnology 18:133.
   PubMed Web of Science ®Google Scholar
• Kozuch PL, Hanauer SB. (2008). Treatment of inflammatory bowel disease: a review of medical therapy. World J Gastroenterol 14:354–77.
   PubMed Web of Science ®Google Scholar
• Labiris NR, Dolovich MB. (2003). Pulmonary drug delivery. I. Physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol 56:588–99.
   PubMed Web of Science ®Google Scholar
• Lautenschläger C, Schmidt C, Fischer D, Stallmach A. (2014). Drug delivery strategies in the therapy of inflammatory bowel disease. Adv Drug Deliv Rev 71:58–76.
   PubMed Web of Science ®Google Scholar
• Lee BC, Lee JY, Kim J, et al. (2020). Graphene quantum dots as anti-inflammatory therapy for colitis. Sci Adv 6:eaaz2630.
   PubMed Web of Science ®Google Scholar
• Lee Y, Sugihara K, Gillilland MGIII, et al. (2020). Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat Mater 19:118–26.
   PubMed Web of Science ®Google Scholar
• Li S, Xie A, Li H, et al. (2019). A self-assembled, ROS-responsive Janus-prodrug for targeted therapy of inflammatory bowel disease. J Control Release 316:66–78.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Abreu MT, Cohen R, Tremaine W, American Gastroenterological Association (2006). American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130:940–87.
   PubMed Web of Science ®Google Scholar
• Lichtiger S, Present DH, Kornbluth A, et al. (1994). Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330:1841–5.
   PubMed Web of Science ®Google Scholar
• Liu L, Yao W, Rao Y, et al. (2017). pH-Responsive carriers for oral drug delivery: challenges and opportunities of current platforms. Drug Deliv 24:569–81.
   PubMed Web of Science ®Google Scholar
• Mao H, Su P, Qiu W, et al. (2016). The use of Masson’s trichrome staining, second harmonic imaging and two-photon excited fluorescence of collagen in distinguishing intestinal tuberculosis from Crohn’s disease. Colorectal Dis 18:1172–8.
   PubMed Web of Science ®Google Scholar
• Marquez Ruiz JF, Kedziora K, Pigott M, et al. (2013). A nitrophenyl-based prodrug type for colorectal targeting of prednisolone, budesonide and celecoxib. Bioorg Med Chem Lett 23:1693–8.
   PubMed Web of Science ®Google Scholar
• Martinez MN, Amidon GL. (2002). A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42:620–43.
   PubMed Web of Science ®Google Scholar
• McKeage K, Goa KL. (2002). Budesonide (Entocort® EC capsules). Drugs 62:2263–82.
   PubMed Web of Science ®Google Scholar
• Molodecky NA, Soon IS, Rabi DM, et al. (2012). Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142:46–54.
   PubMed Web of Science ®Google Scholar
• Narvekar M, Xue HY, Eoh JY, Wong HL. (2014). Nanocarrier for poorly water-soluble anticancer drugs—barriers of translation and solutions. AAPS Pharmscitech 15:822–33.
   PubMed Web of Science ®Google Scholar
• Qiao H, Fang D, Chen J, et al. (2017). Orally delivered polycurcumin responsive to bacterial reduction for targeted therapy of inflammatory bowel disease. Drug Deliv 24:233–42.
   PubMed Web of Science ®Google Scholar
• Ren L, Xu P, Yao J, et al. (2022). Targeting the mitochondria with pseudo-stealthy nanotaxanes to impair mitochondrial biogenesis for effective cancer treatment. ACS Nano 16:10242–59.
   PubMed Web of Science ®Google Scholar
• Saleh M, Trinchieri G. (2011). Innate immune mechanisms of colitis and colitis-associated colorectal cancer. Nat Rev Immunol 11:9–20.
   PubMed Web of Science ®Google Scholar
• Scott SA, Fu J, Chang PV. (2020). Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci USA 117:19376–87.
   PubMed Web of Science ®Google Scholar
• Shahbazi M-A, Santos HA. (2013). Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Curr Drug Metab 14:28–56.
   PubMed Web of Science ®Google Scholar
• Shi L, Wang Y, Wang Q, et al. (2020). Transforming a toxic drug into an efficacious nanomedicine using a lipoprodrug strategy for the treatment of patient-derived melanoma xenografts. J Controlled Release 324:289–302.
   PubMed Web of Science ®Google Scholar
• Silverman JA, Deitcher SR. (2013). Marqibo®(vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol 71:555–64.
   PubMed Web of Science ®Google Scholar
• Stegemann S, Leveiller F, Franchi D, et al. (2007). When poor solubility becomes an issue: from early stage to proof of concept. Eur J Pharm Sci 31:249–61.
   PubMed Web of Science ®Google Scholar
• Thakor AS, Gambhir SS. (2013). Nanooncology: the future of cancer diagnosis and therapy. CA: Cancer J Clin 63:395–418.
   PubMed Web of Science ®Google Scholar
• Ting Y, Jiang Y, Ho C-T, Huang Q. (2014). Common delivery systems for enhancing in vivo bioavailability and biological efficacy of nutraceuticals. J Funct Foods 7:112–28.
   Web of Science ®Google Scholar
• Tsume Y, Mudie DM, Langguth P, et al. (2014). The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci 57:152–63.
   PubMed Web of Science ®Google Scholar
• Van den Mooter G, Kinget R. (1995). Oral colon-specific drug delivery: a review. Drug Deliv 2:81–93.
   Google Scholar
• Vrettos N-N, Roberts CJ, Zhu Z. (2021). Gastroretentive technologies in tandem with controlled-release strategies: a potent answer to oral drug bioavailability and patient compliance implications. Pharmaceutics 13:1591.
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Z, Wang L, et al. (2017). New generation nanomedicines constructed from self-assembling small-molecule prodrugs alleviate cancer drug toxicity. Cancer Res 77:6963–74.
   PubMed Web of Science ®Google Scholar
• Wang H, Wu J, Xie K, et al. (2017). Precise engineering of prodrug cocktails into single polymeric nanoparticles for combination cancer therapy: extended and sequentially controllable drug release. ACS Appl Mater Interfaces 9:10567–76.
   PubMed Web of Science ®Google Scholar
• Wang H, Xie H, Wang J, et al. (2015). Self-assembling prodrugs by precise programming of molecular structures that contribute distinct stability, pharmacokinetics, and antitumor efficacy. Adv Funct Mater 25:4956–65.
   Web of Science ®Google Scholar
• Wang Y, Xie H, Ying K, et al. (2021). Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies. Biomaterials 270:120705.
   PubMed Web of Science ®Google Scholar
• Wu L, Zhang F, Chen X, et al. (2019). Self-assembled gemcitabine prodrug nanoparticles show enhanced efficacy against patient-derived pancreatic ductal adenocarcinoma. ACS Appl Mater Interfaces 12:3327–40.
   Web of Science ®Google Scholar
• Wu L, Zhang F, Chen X, et al. (2020). Self-assembled gemcitabine prodrug nanoparticles show enhanced efficacy against patient-derived pancreatic ductal adenocarcinoma. ACS Appl Mater Interfaces 12:3327–40.
   PubMed Web of Science ®Google Scholar
• Xian J, Zhong X, Gu H, et al. (2021). Colonic delivery of celastrol-loaded layer-by-layer liposomes with pectin/trimethylated chitosan coating to enhance its anti-ulcerative colitis effects. Pharmaceutics 13:2005
   PubMed Web of Science ®Google Scholar
• Xie H, Zhu H, Zhou K, et al. (2020). Target-oriented delivery of self-assembled immunosuppressant cocktails prolongs allogeneic orthotopic liver transplant survival. J Control Release 328:237–50.
   PubMed Web of Science ®Google Scholar
• Xiu Y, Wang K, Chen J, et al. (2020). Liposomal N-acylethanolamine-hydrolyzing acid amidase (NAAA) inhibitor F96 as a new therapy for colitis. RSC Adv 10:34197–202.
   PubMed Web of Science ®Google Scholar
• Yantiss R, Odze R. (2006). Diagnostic difficulties in inflammatory bowel disease pathology. Histopathology 48:116–32.
   PubMed Web of Science ®Google Scholar
• Zhang H. (2016). Onivyde for the therapy of multiple solid tumors. OncoTargets Ther 9:3001.
   PubMed Web of Science ®Google Scholar